PRQR ProQR Therapeutics
- 1.7800
- -0.0200-1.11%
- 1.7800
- 0.00000.00%
ProQR Therapeutics News
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Surge Not Quite Adding Up
ProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | Pro QR Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results
ProQR Therapeutics N.V. Financial Performance Review
Express News | ProQR Therapeutics NV: EUR 96.2 Mln Cash Position as of End of Q2 Providing Runway Into Mid-2026
ProQR Therapeutics 2Q Rev $6.31M >PRQR
Express News | ProQR Announces Second Quarter 2024 Operating and Financial Results
Express News | ProQR Therapeutics Q2 Operating Income EUR -3.6 Million
Express News | ProQR Therapeutics Q2 EPS EUR -0.03 Vs. IBES Estimate EUR -0.12
Institutions Own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares but Retail Investors Control 46% of the Company
ProQR Announces Presentation on Its Axiomer RNA Editing Technology at RNA Editing Summit
Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Express News | HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
ProQR Therapeutics Analyst Ratings
Express News | ProQR Therapeutics' Cash And Cash Equivalents And Short Term Financial Assets Of €102.7M As Of End Of Q1 Provides Runway Into Mid-2026
Express News | ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate
Analysis
Price Target
No Data
No Data